Department of Otolaryngology-Head and Neck Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, New York, U.S.A.
Weill Cornell Medical College, New York, New York, U.S.A.
Laryngoscope. 2021 Dec;131(12):E2849-E2856. doi: 10.1002/lary.29669. Epub 2021 Jun 9.
Report long-term tracheostomy outcomes in patients with COVID-19.
Review of prospectively collected data.
Prospectively collected data were extracted for adults with COVID-19 undergoing percutaneous or open tracheostomy between April 4, 2020 and June 2, 2020 at a major medical center in New York City. The primary endpoint was weaning from mechanical ventilation. Secondary outcomes included sedation weaning, decannulation, and discharge.
One hundred one patients underwent tracheostomy, including 48 percutaneous (48%) and 53 open (52%), after a median intubation time of 24 days (IQR 20, 31). The most common complication was minor bleeding (n = 18, 18%). The all-cause mortality rate was 15% and no deaths were attributable to the tracheostomy. Eighty-three patients (82%) were weaned off mechanical ventilation, 88 patients (87%) were weaned off sedation, and 72 patients (71%) were decannulated. Censored median times from tracheostomy to sedation and ventilator weaning were 8 (95% CI 6-11) and 18 (95% CI 14-22) days, respectively (uncensored: 7 and 15 days). Median time from tracheostomy to decannulation was 36 (95% CI 32-47) days (uncensored: 32 days). Of those decannulated, 82% were decannulated during their index admission. There were no differences in outcomes or complication rates between percutaneous and open tracheostomy. Likelihood of discharge from the ICU was inversely related to intubation time, though the clinical relevance of this was small (HR 0.97, 95% CI 0.943-0.998; P = .037).
Tracheostomy by either percutaneous or open technique facilitated sedation and ventilator weaning in patients with COVID-19 after prolonged intubation. Additional study on the optimal timing of tracheostomy in patients with COVID-19 is warranted.
3 Laryngoscope, 131:E2849-E2856, 2021.
报告 COVID-19 患者长期气管造口术的结果。
回顾性收集数据。
从 2020 年 4 月 4 日至 2020 年 6 月 2 日,在纽约市一家主要医疗中心对接受经皮或开放性气管造口术的 COVID-19 成人患者前瞻性收集的数据进行提取。主要终点是从机械通气中脱机。次要结局包括镇静脱机、拔管和出院。
101 例患者接受了气管造口术,其中经皮(48%)48 例,开放性(52%)53 例,中位插管时间为 24 天(IQR 20,31)。最常见的并发症是轻微出血(n=18,18%)。总死亡率为 15%,无死亡归因于气管造口术。83 例(82%)患者成功脱机,88 例(87%)患者成功脱镇静,72 例(71%)患者成功拔管。从气管造口术到镇静和呼吸机脱机的中位时间分别为 8(95%CI 6-11)和 18(95%CI 14-22)天(未删失:7 和 15 天)。从气管造口术到拔管的中位时间为 36(95%CI 32-47)天(未删失:32 天)。在拔管的患者中,82%在指数住院期间拔管。经皮与开放性气管造口术的结果或并发症发生率无差异。从 ICU 出院的可能性与插管时间呈反比,但临床相关性较小(HR 0.97,95%CI 0.943-0.998;P=0.037)。
经皮或开放性技术的气管造口术有助于 COVID-19 患者在长时间插管后进行镇静和呼吸机脱机。需要进一步研究 COVID-19 患者气管造口术的最佳时机。
3 级喉镜,131:E2849-E2856,2021 年。